We already reported that World Health Organisation (WHO) has approved Bharat Biotech’s Covaxin for emergency use. Now, one of the world’s top medical journals, Lancet has published that the made-in-India vaccine is 77.8 per cent effective against symptomatic Covid. The vaccine demonstrated these results in the phase 3 data.
The efficacy data showed 70.8 per cent protection against all variants of the SARS-CoV-2 virus. As per the phase 3 data, the homemade vaccine was found to be 65.2% effective against the Delta variant, 93.4% effective against severe symptomatic Coronavirus and 63.6% effective against asymptomatic Covid.
“We estimated vaccine efficacy of 77·8% against symptomatic Covid-19 disease and, importantly, based on the limited data available, a higher efficacy against severe Covid-19 of 93·4%,” the manufacturer of the vaccine reported.
The domestic vaccine’s phase 3 clinical trials were carried out in 25 hospitals between November 2020 and May 2021, involving 24,419 participants aged 18-97 years.